ScreenerHero

CARM Carisma Therapeutics, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · carismatx.com
0.0007USD-12.50%Mkt Cap: 33476 $P/E: 0.00

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap33.48K USD
Enterprise Value-1.98M USD
Revenue (TTM)52.63M USD
Gross Profit25.28M USD
Net Income (TTM)-60.48M USD
Revenue/Share1.26 USD
Last Price0.0007 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees46
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.00
P/E (Forward)-0.00
PEG—
EV/EBITDA-0.14
EV/Revenue-0.04
P/S0.00
P/B-0.03
EPS (TTM)0.19
EPS (Forward)-0.91
52W Range
0.00010% of range0.4139
52W High0.4139 USD
52W Low0.0001 USD
Profitability
Gross Margin48.03%
Oper. Margin96.83%
EBITDA Margin26.94%
Profit Margin-308.05%
ROE216.69%
ROA-198.56%
Growth
Revenue Growth1236.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-59.92M USD
CapEx (TTM)123.00K USD
FCF Margin24.79%
FCF Yield38975.31%
Net Debt-2.02M USD
Net Debt/EBITDA-0.14
Balance Sheet
Debt/Equity-0.09
Current Ratio0.86
Quick Ratio0.65
Book Value/Sh-0.02 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 8, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.41.85M
Float30.14M
Insiders23.04%
Institutions10.79%
Short Interest
Short Ratio0.1d
Short % Float3.57%
Short % Out.3.09%
Shares Short1.29M
Short (prev mo.)787.46K
Technical
SMA 500.0020 (-65.4%)
SMA 2000.0189 (-96.3%)
Beta-29.21
S&P 52W Chg15.96%
Avg Vol (30d)10.58K
Avg Vol (10d)2.60K
Technical Indicators
RSI (14)31.8
MACD-0.0007
MACD Signal-0.0008
MACD Hist.+0.0001
BB Upper0.0024 USD
BB Middle0.0012 USD
BB Lower-0.0000 USD
BB Width203.92%
ATR (14)0.0004 USD
Vol Ratio (20d)0.04x